(United States Federal Circuit) - In an appeal of the inter partes review decision of the Patent Trial and Appeal Board (PTAB) finding certain claims of a patent that relates to 'huMab4D5 ANTI-ErbB2 antibody-maytansinoid conjugates' as nonobvious,the matter is dismissed where plaintiff has not offered sufficient proof establishing that it has suffered an injury in fact, and thus, and it lacks standing to bring suit in federal court.
Source: findlaw.com